The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Middle Aged

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Middle Aged.
Marina Chiara Garassino
Connection Strength
1.138
Middle Aged
  1. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024 Aug 20; 42(24):2860-2872.
    View in: PubMed
    Score: 0.059
  2. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021 05; 149:235-248.
    View in: PubMed
    Score: 0.048
  3. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020 07; 21(7):914-922.
    View in: PubMed
    Score: 0.045
  4. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 03; 21(3):387-397.
    View in: PubMed
    Score: 0.044
  5. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program. Tumour Biol. 2018 Nov; 40(11):1010428318815047.
    View in: PubMed
    Score: 0.040
  6. Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018 08; 13(8):1146-1155.
    View in: PubMed
    Score: 0.039
  7. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 May 31; 378(22):2078-2092.
    View in: PubMed
    Score: 0.039
  8. Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. Lancet Oncol. 2018 04; 19(4):521-536.
    View in: PubMed
    Score: 0.039
  9. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013 Sep; 14(10):981-8.
    View in: PubMed
    Score: 0.028
  10. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One. 2013; 8(4):e59981.
    View in: PubMed
    Score: 0.027
  11. Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: a multi-institutional retrospective analysis. Lung Cancer. 2011 Jun; 72(3):378-83.
    View in: PubMed
    Score: 0.023
  12. Determinants of 5-year survival in patients with advanced NSCLC with PD-L1=50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry. J Immunother Cancer. 2025 Feb 04; 13(2).
    View in: PubMed
    Score: 0.016
  13. Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review. Lung Cancer. 2025 Jan; 199:108051.
    View in: PubMed
    Score: 0.015
  14. Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2024 Sep 28; 404(10459):1240-1252.
    View in: PubMed
    Score: 0.015
  15. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2025 Jan 20; 43(3):260-272.
    View in: PubMed
    Score: 0.015
  16. Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study. BMC Cancer. 2024 Jul 25; 23(Suppl 1):1250.
    View in: PubMed
    Score: 0.015
  17. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study. Mol Cancer. 2024 May 30; 23(1):115.
    View in: PubMed
    Score: 0.015
  18. Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial. Oncologist. 2024 May 03; 29(5):e690-e698.
    View in: PubMed
    Score: 0.015
  19. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024 Aug; 19(8):1228-1241.
    View in: PubMed
    Score: 0.015
  20. Nivolumab in pretreated pleural mesothelioma: Results from an observational real-world study of patients treated within the AIFA 5% Fund. Tumori. 2024 Jun; 110(3):168-173.
    View in: PubMed
    Score: 0.015
  21. Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. J Clin Oncol. 2022 03 01; 40(7):710-718.
    View in: PubMed
    Score: 0.012
  22. Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer. Cancer Discov. 2022 01; 12(1):90-107.
    View in: PubMed
    Score: 0.012
  23. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2021 10; 22(10):1438-1447.
    View in: PubMed
    Score: 0.012
  24. Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology. Clin Lung Cancer. 2022 01; 23(1):e17-e28.
    View in: PubMed
    Score: 0.012
  25. Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey. ESMO Open. 2021 06; 6(3):100131.
    View in: PubMed
    Score: 0.012
  26. Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer. 2021 07; 157:9-16.
    View in: PubMed
    Score: 0.012
  27. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.012
  28. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). Clin Lung Cancer. 2021 07; 22(4):301-312.e8.
    View in: PubMed
    Score: 0.012
  29. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. J Clin Oncol. 2021 03 01; 39(7):723-733.
    View in: PubMed
    Score: 0.012
  30. Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy. ESMO Open. 2021 04; 6(2):100053.
    View in: PubMed
    Score: 0.012
  31. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). J Clin Oncol. 2021 02 20; 39(6):619-630.
    View in: PubMed
    Score: 0.012
  32. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021 01; 22(1):51-65.
    View in: PubMed
    Score: 0.012
  33. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2021 03; 22(2):e180-e192.
    View in: PubMed
    Score: 0.012
  34. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020 11 15; 126(22):4867-4877.
    View in: PubMed
    Score: 0.011
  35. Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score =50% treated with front-line pembrolizumab. Acta Oncol. 2020 Sep; 59(9):1058-1063.
    View in: PubMed
    Score: 0.011
  36. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943.
    View in: PubMed
    Score: 0.011
  37. Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. Thorac Cancer. 2020 06; 11(6):1661-1669.
    View in: PubMed
    Score: 0.011
  38. Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020 05 10; 38(14):1505-1517.
    View in: PubMed
    Score: 0.011
  39. Relationship Between Programmed Death Receptor-Ligand 1 Expression and Response to Checkpoint Inhibitor Immunotherapy in Pulmonary Sarcomatoid Carcinoma: A Pooled Analysis. Clin Lung Cancer. 2020 09; 21(5):e456-e463.
    View in: PubMed
    Score: 0.011
  40. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. Clin Lung Cancer. 2020 09; 21(5):e337-e348.
    View in: PubMed
    Score: 0.011
  41. Incidence of T790M in Patients With NSCLC Progressed to Gefitinib, Erlotinib, and Afatinib: A Study on Circulating Cell-free DNA. Clin Lung Cancer. 2020 05; 21(3):232-237.
    View in: PubMed
    Score: 0.011
  42. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer. Tumori. 2019 Dec; 105(6):NP57-NP62.
    View in: PubMed
    Score: 0.011
  43. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019 10; 20(10):1395-1408.
    View in: PubMed
    Score: 0.011
  44. Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. Future Oncol. 2019 Aug; 15(23):2743-2757.
    View in: PubMed
    Score: 0.011
  45. Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. J Thorac Oncol. 2019 08; 14(8):1390-1399.
    View in: PubMed
    Score: 0.010
  46. Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Lung Cancer. 2019 06; 132:72-78.
    View in: PubMed
    Score: 0.010
  47. Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial. Lung Cancer. 2019 06; 132:17-23.
    View in: PubMed
    Score: 0.010
  48. Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer. Lung Cancer. 2019 03; 129:35-40.
    View in: PubMed
    Score: 0.010
  49. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. Eur J Cancer. 2019 02; 108:120-128.
    View in: PubMed
    Score: 0.010
  50. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study. Clin Cancer Res. 2019 04 01; 25(7):2166-2173.
    View in: PubMed
    Score: 0.010
  51. Exploiting FAsting-mimicking Diet and MEtformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. Clin Lung Cancer. 2019 05; 20(3):e413-e417.
    View in: PubMed
    Score: 0.010
  52. Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. Target Oncol. 2018 12; 13(6):795-800.
    View in: PubMed
    Score: 0.010
  53. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol. 2018 11; 19(11):1468-1479.
    View in: PubMed
    Score: 0.010
  54. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018 11; 13(11):1692-1704.
    View in: PubMed
    Score: 0.010
  55. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018 09 10; 36(26):2702-2709.
    View in: PubMed
    Score: 0.010
  56. RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. Clin Lung Cancer. 2018 09; 19(5):e811-e814.
    View in: PubMed
    Score: 0.010
  57. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018 04 01; 29(4):959-965.
    View in: PubMed
    Score: 0.010
  58. Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. Lung Cancer. 2018 01; 115:135-142.
    View in: PubMed
    Score: 0.009
  59. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789.
    View in: PubMed
    Score: 0.009
  60. The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. Sci Rep. 2016 12 14; 6:39217.
    View in: PubMed
    Score: 0.009
  61. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 02 16; 376(7):629-640.
    View in: PubMed
    Score: 0.009
  62. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respir Res. 2016 08 25; 17(1):105.
    View in: PubMed
    Score: 0.009
  63. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. Virchows Arch. 2016 Jun; 468(6):651-62.
    View in: PubMed
    Score: 0.008
  64. Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. Virchows Arch. 2016 Apr; 468(4):451-61.
    View in: PubMed
    Score: 0.008
  65. Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). Sci Rep. 2015 Nov 17; 5:16331.
    View in: PubMed
    Score: 0.008
  66. Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. J Thorac Oncol. 2015 Nov; 10(11):1560-9.
    View in: PubMed
    Score: 0.008
  67. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. Oncotarget. 2015 Oct 20; 6(32):34014-22.
    View in: PubMed
    Score: 0.008
  68. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Jul 09; 373(2):123-35.
    View in: PubMed
    Score: 0.008
  69. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014 Mar; 9(3):390-6.
    View in: PubMed
    Score: 0.007
  70. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol. 2014 Apr; 22(2):136-48.
    View in: PubMed
    Score: 0.007
  71. Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers. Tumori. 2013 Sep-Oct; 99(5):596-600.
    View in: PubMed
    Score: 0.007
  72. ?Np63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol. 2013 Jun; 21(3):229-39.
    View in: PubMed
    Score: 0.007
  73. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012 Sep; 77(3):507-14.
    View in: PubMed
    Score: 0.006
  74. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012 Mar; 75(3):360-7.
    View in: PubMed
    Score: 0.006
  75. A mono-institutional prospective study on the effectiveness of a specialist psychotherapeutic intervention (POI) started at the diagnosis of cancer. Support Care Cancer. 2012 Mar; 20(3):475-81.
    View in: PubMed
    Score: 0.006
  76. Clinical and molecular determinants of survival in pancreatic cancer patients treated with second-line chemotherapy: results of an Italian/Swiss multicenter survey. Anticancer Res. 2010 Oct; 30(10):4289-95.
    View in: PubMed
    Score: 0.006
  77. Darbepoetin alfa administered every three weeks (Q3W) in anemic cancer patients receiving chemotherapy (CT). Anticancer Res. 2008 May-Jun; 28(3B):1767-71.
    View in: PubMed
    Score: 0.005
  78. An oxaliplatin + 5-fluorouracil bolus + folinic acid (BFOL) regimen as first-line treatment in metastatic colorectal cancer patients. Tumori. 2007 Nov-Dec; 93(6):557-61.
    View in: PubMed
    Score: 0.005
  79. Reversible palpebral ptosis following oxaliplatin infusion. Dig Liver Dis. 2007 Nov; 39(11):1041.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.